Strive Health, a leader in value-based kidney care, today announced that Rich Whitney has joined the company’s Board of Directors. He currently serves as the Chairman and CEO of Radiology Partners.
“Rich is a deeply experienced healthcare leader and entrepreneur who has been at the forefront of changing many areas of healthcare delivery, including kidney care,” said Chris Riopelle, CEO of Strive Health. “He brings outstanding depth and market knowledge that complements our innovative approach to value-based kidney care. Rich will be an asset to our board and instrumental in our next phase of growth.”
Rich has spent his career in healthcare services, establishing a long track record of leading, founding and investing in healthcare organizations that have made meaningful change. At Radiology Partners, he has led the company from startup to approximately $2 billion in revenue. As CFO and senior advisor to the CEO of kidney dialysis provider, DaVita, Inc., Rich was integral in growing the company to $11 billion in revenue and over $20 billion in enterprise value.
Since the mid-2000’s Rich has also been an investor, director and/or chairman of entrepreneurial healthcare companies in areas such as pathology, physician services, clinical laboratories, dialysis, hospitals and behavioral health. He currently serves on the Board of CHG Healthcare and National Veterinary Associates, and has also served as a venture partner and advisor to NEA since 2007.
“Treating kidney disease is expensive and holds many opportunities to improve the patient journey,” said Whitney. “Strive Health is transforming the traditional approach to kidney care with advanced technology and high-touch care teams that lower costs and help patients lead better lives. I am excited to join the Board and work with the team.”
Kidney disease impacts 37 million Americans, most of whom are unaware they have it. A proactive, value-based approach is required for earlier intervention that promotes patient health and well-being. Strive Health integrates technology, including proprietary machine learning algorithms, and clinical infrastructure to improve health outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).